Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis

CONCLUSIONS: In this real-world analysis of patients with TNBC treated with NAC plus pembro, younger age and the completion of at least 8 cycles of pembrolizumab were associated with pCR.PMID:38656345 | DOI:10.1093/oncolo/oyae064

Source: The Oncologist - April 24, 2024 Category: Cancer & Oncology Authors: Alexis LeVee Megan Wong Sarah Flores Nora Ruel Heather McArthur James Waisman Joanne Mortimer Source Type: research